B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討

書誌事項

タイトル別名
  • Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B
  • Bガタ マンセイ カン シッカン ニ タイスル カクサン アナログ リョウホウ ニ ヨル HBs コウゲン ショウシツ ト ソノ カンレン インシ ノ ケントウ

この論文をさがす

抄録

Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance.<br>

収録刊行物

  • 肝臓

    肝臓 52 (4), 255-257, 2011

    一般社団法人 日本肝臓学会

参考文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ